Interpace Biosciences Presented Two New Posters at the 2025 American Thyroid Association® (ATA) Annual Meeting Sep 15, 2025
Effective May 2, 2025, Interpace Diagnostics® Will No Longer Accept Specimens for PancraGEN®, a Molecular Diagnostic Test That Assesses Pancreatic Cyst Cancer Risk Apr 24, 2025
Interpace Biosciences Announces Preliminary Full-year and Fourth Quarter 2024 Financial and Business Results Jan 31, 2025
PancraGEN® Will Continue to be Offered While Interpace Re-evaluates its Previously Announced Re-structuring Plan Jan 27, 2025
Effective 02/07/2025, Interpace Diagnostics® to No Longer Offer PancraGEN®, a Molecular Diagnostic Test That Assesses Pancreatic Cyst Cancer Risk Jan 9, 2025
Interpace Biosciences Announces Capital Restructuring of Its Preferred Stock as a First Step Toward Seeking an Uplisting of Its Common Stock to Nasdaq Oct 15, 2024
Interpace Biosciences Announces Record Second Quarter 2024 Financial and Business Results Aug 1, 2024
